Raub Brock Capital Management LP Decreased By $379,562 Its Amgen (AMGN) Stake; Concert Pharmaceuticals, Inc. (CNCE) Covered By 9 Bullish Analysts Last Week

April 2, 2018 - By Danny Collins

Amgen Inc. (NASDAQ:AMGN) Logo

Raub Brock Capital Management Lp decreased Amgen Inc. (AMGN) stake by 2.39% reported in 2017Q4 SEC filing. Raub Brock Capital Management Lp sold 2,194 shares as Amgen Inc. (AMGN)’s stock declined 2.99%. The Raub Brock Capital Management Lp holds 89,763 shares with $15.61M value, down from 91,957 last quarter. Amgen Inc. now has $122.84 billion valuation. The stock increased 0.01% or $0.02 during the last trading session, reaching $170.48. About 3.77M shares traded. Amgen Inc. (NASDAQ:AMGN) has risen 3.78% since April 2, 2017 and is uptrending. It has underperformed by 7.77% the S&P500.

Among 9 analysts covering Concert Pharmaceuticals (NASDAQ:CNCE), 9 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Concert Pharmaceuticals has $34.0 highest and $20.0 lowest target. $27.89’s average target is 21.79% above currents $22.9 stock price. Concert Pharmaceuticals had 24 analyst reports since August 12, 2015 according to SRatingsIntel. On Friday, March 2 the stock rating was maintained by H.C. Wainwright with “Buy”. On Monday, June 12 the stock rating was maintained by Aegis Capital with “Buy”. The company was initiated on Wednesday, August 12 by Brean Capital. The firm has “Buy” rating given on Monday, November 6 by Mizuho. The firm earned “Buy” rating on Tuesday, September 22 by TH Capital. The stock of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) earned “Buy” rating by H.C. Wainwright on Friday, October 20. The rating was maintained by JMP Securities with “Market Outperform” on Wednesday, March 9. The stock of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) earned “Buy” rating by Stifel Nicolaus on Friday, January 12. Stifel Nicolaus maintained the shares of CNCE in report on Thursday, October 19 with “Buy” rating. The rating was maintained by H.C. Wainwright on Friday, November 10 with “Buy”. See Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) latest ratings:

09/03/2018 Broker: Mizuho Rating: Buy New Target: $27.0 Upgrade
02/03/2018 Broker: H.C. Wainwright Old Rating: Buy New Rating: Buy Old Target: $21 New Target: $25 Maintain
12/01/2018 Broker: Stifel Nicolaus Rating: Buy New Target: $27.0 Maintain
12/01/2018 Broker: Mizuho Old Rating: Buy New Rating: Neutral Old Target: $23 New Target: $23 Downgrade
19/12/2017 Broker: UBS Rating: Buy New Target: $34.0 Maintain
10/11/2017 Broker: H.C. Wainwright Rating: Buy New Target: $21.0 Maintain
06/11/2017 Broker: Mizuho Rating: Buy New Target: $23.0 Maintain
26/10/2017 Broker: Mizuho Rating: Buy New Target: $23 Initiates Coverage On
19/10/2017 Broker: Stifel Nicolaus Rating: Buy New Target: $30.0 Maintain
20/10/2017 Broker: H.C. Wainwright Rating: Buy New Target: $21.0 Maintain

The stock increased 4.47% or $0.98 during the last trading session, reaching $22.9. About 363,640 shares traded. Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) has risen 26.05% since April 2, 2017 and is uptrending. It has outperformed by 14.50% the S&P500.

Investors sentiment increased to 2.62 in 2017 Q4. Its up 1.44, from 1.18 in 2017Q3. It increased, as 10 investors sold Concert Pharmaceuticals, Inc. shares while 19 reduced holdings. 42 funds opened positions while 34 raised stakes. 15.49 million shares or 6.32% more from 14.57 million shares in 2017Q3 were reported. Parametric Associates Lc reported 0% stake. Clarivest Asset Llc has invested 0.01% of its portfolio in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE). Vanguard accumulated 776,375 shares. Bvf Il stated it has 6.14% of its portfolio in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE). 292,010 were reported by Bogle Management L P De. Zurcher Kantonalbank (Zurich Cantonalbank) owns 0% invested in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) for 5,668 shares. 98,786 were reported by Goldman Sachs. 88,705 were accumulated by Qs Limited Liability Company. California State Teachers Retirement System reported 28,249 shares or 0% of all its holdings. Schwab Charles Management reported 36,621 shares stake. Gotham Asset Ltd holds 15,530 shares or 0.01% of its portfolio. Blackrock Incorporated holds 0% of its portfolio in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) for 1.79M shares. Vermont-based Manchester Capital Mgmt Limited Liability Corp has invested 0.08% in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE). Eam Limited Liability accumulated 74,232 shares. Plante Moran Ltd Liability Company has invested 0.03% of its portfolio in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE).

Since October 19, 2017, it had 1 buy, and 5 selling transactions for $2.87 million activity. ALDRICH RICHARD also sold $597,833 worth of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) on Tuesday, January 16. BVF PARTNERS L P/IL bought $5.26 million worth of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) on Thursday, October 19.

Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company. The company has market cap of $532.04 million. It discovers and develops novel small molecule drugs for use in the treatment of various pulmonary diseases, including cystic fibrosis, autoimmune and inflammatory diseases, and central nervous systems disorders. It has a 5.64 P/E ratio. The companyÂ’s clinical-stage product candidates include AVP-786, which is in Phase 3 clinical trials for the treatment of neurologic and psychiatric disorders, including agitation associated with AlzheimerÂ’s disease; and CTP-656, which is in Phase 2 clinical trials to treat cystic fibrosis.

Analysts await Amgen Inc. (NASDAQ:AMGN) to report earnings on April, 25. They expect $3.21 earnings per share, up 1.90% or $0.06 from last year’s $3.15 per share. AMGN’s profit will be $2.31 billion for 13.28 P/E if the $3.21 EPS becomes a reality. After $2.89 actual earnings per share reported by Amgen Inc. for the previous quarter, Wall Street now forecasts 11.07% EPS growth.

Since October 9, 2017, it had 0 insider purchases, and 5 sales for $1.39 million activity. The insider Harper Sean E sold $265,625.

Investors sentiment increased to 1.22 in Q4 2017. Its up 0.23, from 0.99 in 2017Q3. It increased, as 73 investors sold AMGN shares while 458 reduced holdings. 122 funds opened positions while 527 raised stakes. 551.71 million shares or 0.60% less from 555.05 million shares in 2017Q3 were reported. Quantres Asset reported 2,300 shares. Denver Invest Ltd Liability Co holds 0.81% or 93,036 shares. Seabridge Inv Advsr Ltd Liability Co accumulated 18,753 shares. Schafer Cullen Cap Management, New York-based fund reported 2,475 shares. 99,781 were reported by Alpha Cubed Investments Limited Liability Corporation. Carderock Cap Mgmt invested 2.05% in Amgen Inc. (NASDAQ:AMGN). The California-based Denali Advisors Limited Liability Corporation has invested 0.17% in Amgen Inc. (NASDAQ:AMGN). Franklin Street Advisors Nc holds 0.07% of its portfolio in Amgen Inc. (NASDAQ:AMGN) for 2,803 shares. Supplemental Annuity Collective Tru Of Nj accumulated 0.66% or 9,000 shares. Livingston Grp Incorporated Asset Management (Operating As Southport Capital Management) reported 0.22% in Amgen Inc. (NASDAQ:AMGN). The New York-based Jpmorgan Chase Communications has invested 0.1% in Amgen Inc. (NASDAQ:AMGN). Fiduciary Com holds 0.42% in Amgen Inc. (NASDAQ:AMGN) or 81,829 shares. Chatham Capital Gru Inc stated it has 0.08% of its portfolio in Amgen Inc. (NASDAQ:AMGN). Greenwood Ltd Limited Liability Company invested in 15,566 shares. First Advsr Lp accumulated 630,183 shares.

Among 25 analysts covering Amgen Inc. (NASDAQ:AMGN), 11 have Buy rating, 0 Sell and 14 Hold. Therefore 44% are positive. Amgen Inc. has $220 highest and $160 lowest target. $193.66’s average target is 13.60% above currents $170.48 stock price. Amgen Inc. had 87 analyst reports since August 3, 2015 according to SRatingsIntel. As per Tuesday, December 20, the company rating was downgraded by Credit Suisse. The stock of Amgen Inc. (NASDAQ:AMGN) earned “Outperform” rating by Credit Suisse on Wednesday, January 20. The rating was maintained by Oppenheimer with “Buy” on Wednesday, August 23. Raymond James initiated the stock with “Market Perform” rating in Tuesday, September 1 report. The rating was reinitiated by Jefferies with “Buy” on Tuesday, July 11. Vetr upgraded the stock to “Buy” rating in Friday, August 21 report. JP Morgan maintained Amgen Inc. (NASDAQ:AMGN) on Wednesday, January 24 with “Neutral” rating. The company was maintained on Friday, February 2 by PiperJaffray. The company was maintained on Tuesday, August 29 by Oppenheimer. The stock of Amgen Inc. (NASDAQ:AMGN) earned “Outperform” rating by Oppenheimer on Tuesday, December 13.

Amgen Inc. (NASDAQ:AMGN) Institutional Positions Chart